關(guān)鍵詞： Enanta 丙肝 IPO
2013年3月20日訊 /生物谷BIOON/ -- 美國制藥公司Enanta公司計劃憑借公司研發(fā)的丙肝藥物項目進行總值高達7300萬美元的募資,。2012年,，Enanta公司曾宣布,，公司與Abbott公司聯(lián)合研發(fā)的藥物--一種ribavirin和ABT-072合劑--取得很大進展，在當(dāng)時引起轟動,。
而公司的主要競爭對手Gilead公司治療丙肝的藥物目前則正在將其晚期研究數(shù)據(jù)送往FDA審核。（生物谷Bioon.com）
詳細英文報道：
Watertown, MA-based Enanta Pharmaceuticals is about to find out if one of the hottest products in late-stage development for hepatitis C can excite investors about its $73 million IPO. The biotech has priced 4 million shares at $14 to $16 apiece, betting that its big role in a closely-watched hepatitis C study will provide enough cash to fund the developer for some time to come. And underwriters have the option of picking up 600,000 shares.
Enanta has a pipeline of products, but its ABT-450, a crucial piece of AbbVie's Phase III hep C program, that it's resting the bulk of its hopes on. In the spring of 2012 Enanta and Abbott ($ABT) announced that the protease inhibitor--developed by the two companies in a collaboration--along with ribavirin and ABT-072 in an interferon-free combo delivered a sustained viral response at 24 weeks after 12 weeks of treatment for 91% of genotype 1 patients. And 82% of patients achieved SVR 36.
That data helped Enanta win recognition as a 2012 Fierce 15 company.
AbbVie's big rival in the hep C race is Gilead ($GILD), which is already on its way to the FDA with late-stage data from a slate of studies. But analysts expect several cocktails will eventually share a growing multibillion dollar market. And AbbVie has been committing a big share of its R&D resources to come in close behind Gilead. In the S-1, Enanta estimates that an NDA for the program should be ready in about two years.
That ambition has paid off for Enanta, which says it has rounded up an impressive $189 million in partnership cash and venture funds, according to its amended S-1. Then there's $430 million in potential development milestones from AbbVie and Novartis--partnered on an NS5A inhibitor--plus $240 million for approvals and sales milestones and a tiered royalty deal.
In a common ploy, Enanta's insiders have pledged to buy close to 1.5 million shares, or about 38% of the total. Its shares will be traded as $ENTA.
Biotech IPOs have had mixed results in recent months, but with the market up to record highs after years of seeing little or no traction in the public markets, a number of drug developers have been lining up to file IPOs. Tetraphase, another Massachusetts Fierce 15 company, is also going public this week.
(責(zé)任編輯：yan.mao)
